HOWL SEC Filings: 8-K, 10-Q, S-3 & 424B

Financials

TYPE

HEADLINE

FILED AT

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Jul 31, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 7, 2026

10-K

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Mar 27, 2026

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Nov 4, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Aug 14, 2025

10-Q

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

May 8, 2025

News

TYPE

HEADLINE

FILED AT

8-K

NEWWerewolf Therapeutics Announces Positive Clinical Data for WTX-124 and WTX-330 at the SITC 2026 Annual Meeting

Nov 9, 2026

8-K

Werewolf Therapeutics and Ambros Therapeutics Announce Merger Agreement and Concurrent $150 Million Private Placement

Aug 21, 2026

8-K

Werewolf Therapeutics Enters Asset Purchase and License Agreements with EMD Serono

Aug 20, 2026

8-K

Werewolf Therapeutics Reports Second Quarter 2026 Financial Results and Strategic Updates

Jul 31, 2026

8-K

Werewolf Therapeutics Reports Q1 2026 Financial Results and Asset Sale of JZP898 to Jazz Pharmaceuticals

May 7, 2026

8-K

Werewolf Therapeutics Initiates Strategic Review Process to Maximize Shareholder Value

Mar 27, 2026

Prospectus

TYPE

HEADLINE

FILED AT

425

Form 425 - Prospectuses and communications, business combinations

Aug 21, 2026

424B5

ATM | Offering amount: $14,437,740 | Amount sold to date: $10,562,260 | Float: 29,686,472

Mar 11, 2025

424B5

ATM | Offering amount: $25,000,000 | Amount sold to date: $50,000,000

Feb 9, 2024

424B4

OFFERING | Shares amount: 7,500,000 | Share price: $16.00 | Offering amount: $120,000,000.00

Apr 30, 2021

Registrations

TYPE

HEADLINE

FILED AT

S-4/A

Form S-4/A - Registration of securities, business combinations: [Amend]

Oct 26, 2026

S-4

Form S-4 - Registration of securities, business combinations

Sep 22, 2026

S-3

May 2025 SHELF & ATM

May 8, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

May 8, 2025

S-8

Form S-8 - Securities to be offered to employees in employee benefit plans

Mar 11, 2025

S-8 POS

Registration

Aug 8, 2024

Proxies

TYPE

HEADLINE

FILED AT

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 28, 2025

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 28, 2025

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 12, 2024

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 12, 2024

DEFA14A

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Apr 27, 2023

DEF 14A

Form DEF 14A - Other definitive proxy statements

Apr 27, 2023

Ownerships

TYPE

HEADLINE

FILED AT

S-4/A

Form S-4/A - Registration of securities, business combinations: [Amend]

Oct 26, 2026

S-4

Form S-4 - Registration of securities, business combinations

Sep 22, 2026

SCHEDULE 13G

MOLL PETER (Filed by)

Sep 21, 2026

EVNIN LUKE (Reporting)

Jul 8, 2026

144

Form 144 - Report of proposed sale of securities

Jul 6, 2026

144

Form 144 - Report of proposed sale of securities

Jul 6, 2026

Other

TYPE

HEADLINE

FILED AT

EFFECT

Form EFFECT - Notice of Effectiveness

May 16, 2025

CORRESP

Form CORRESP - Correspondence

May 13, 2025

LETTER

Form UPLOAD - SEC-generated letter

May 12, 2025

EFFECT

Form EFFECT - Notice of Effectiveness

May 23, 2022

CORRESP

Form CORRESP - Correspondence

May 18, 2022

LETTER

Form UPLOAD - SEC-generated letter

May 13, 2022

Werewolf Therapeutics, Inc. HOWL · SEC Filings